Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

NCT04816526 is registered in ClinicalTrials.gov with Cartesian Therapeutics as lead sponsor.

NCT NCT04816526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04816526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Lead sponsor
Cartesian Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
December 1, 2021
Completion date
November 3, 2022
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma multiple